A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus

References

• The global burden. Brussels, Belgium: International Diabetes Federation, 2012. Available at: http://www.idf.org/diabetesatlas/5e/the-global-burden [Last accessed 29 October 2013]
   Google Scholar
• The World Health Report 2002. Geneva, Switzerland: World Health Organization, 2002. Available at: http://www.who.int/whr/2002/en/whr02_en.pdf [Last accessed 29 October 2013]
   Google Scholar
• Outline for the Results of the National Health and Nutrition Survey Japan, 2007. Tokyo, Japan: Ministry of Health, Labour and Welfare, 2007. Available at: http://www.nih.go.jp/eiken/english/research/pdf/nhns2007.pdf [Last accessed 29 October 2013]
   Google Scholar
• Fukushima M, Usami M, Ikeda M, et al. Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross-sectional study of Japanese type 2 diabetes. Metabolism 2004;53:831-5
   PubMed Web of Science ®Google Scholar
• Katakura M, Komatsu M, Sato Y, et al. Primacy of beta-cell dysfunction in the development of hyperglycemia: a study in the Japanese general population. Metabolism 2004;53:949-53
   PubMed Web of Science ®Google Scholar
• Boffetta P, McLerran D, Chen Y, et al. Body mass index and diabetes in Asia: a cross-sectional pooled analysis of 900,000 individuals in the Asia cohort consortium. PLoS One 2011;6:e19930
   PubMed Web of Science ®Google Scholar
• Treatment Guide for Diabetes 2007. Tokyo, Japan: Japan Diabetes Society; 2007. Available at: http://www.jds.or.jp/modules/en/index.php?content_id=35 [Last accessed 29 October 2013]
   Google Scholar
• Zander M, Madsbad S, Madsen JL, et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824-30
   PubMed Web of Science ®Google Scholar
• Farilla L, Hui H, Bertolotto C, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002;143:4397-408
   PubMed Web of Science ®Google Scholar
• Nauck MA, Wollschlager D, Werner J, et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 1996;39:1546-53
   PubMed Web of Science ®Google Scholar
• Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Investig 2010;1:8-23
   PubMed Web of Science ®Google Scholar
• Seino Y, Yabe D. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: incretin actions beyond the pancreas. J Diabetes Investig 2013;4:108-30
   PubMed Web of Science ®Google Scholar
• Vilsboll T, Agerso H, Krarup T, et al. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003;88:220-4
   PubMed Web of Science ®Google Scholar
• Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993;214:829-35
   PubMedGoogle Scholar
• Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals Inc., 2011. Available at: http://documents.byetta.com/Byetta_PI.pdf [Last accessed 29 October 2013]
   Google Scholar
• Victoza [package insert]. Plainsboro, NJ: Novo Nordisk Inc., 2010. Available at: http://www.novo-pi.com/victoza.pdf [Last accessed 29 October 2013]
   Google Scholar
• Yabe D, Kuroe A, Lee S, et al. Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: comparison of type 2 diabetes patients and healthy controls. J Diabetes Investig 2010;1:56-9
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Stewart MW. Albiglutide. Glucagon-like peptide GLP-1 receptor agonist, treatment of type 2 diabetes. Drugs Future 2010;35:701-12
   Web of Science ®Google Scholar
• Rosenstock J, Reusch J, Bush M, et al. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 2009;32:1880-6
   PubMed Web of Science ®Google Scholar
• Matthews JE, Stewart MW, De Boever EH, et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab 2008;93:4810-17
   PubMed Web of Science ®Google Scholar
• Seino Y, Nakajima H, Miyahara H, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus. Curr Med Res Opin 2009;25:3049-57
   PubMed Web of Science ®Google Scholar
• , The Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes MellitusSeino Y, Nanjo K, et al. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig 2010;1:212-28
   PubMed Web of Science ®Google Scholar
• Li Y, Hansotia T, Yusta B, et al. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 2003;278:471-8
   PubMed Web of Science ®Google Scholar
• Monami M, Dicembrini I, Marchionni N, et al. Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis. Exp Diabetes Res 2012;2012:672658
   PubMedGoogle Scholar
• Vilsboll T, Christensen M, Junker AE, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012;344:d7771
   PubMed Web of Science ®Google Scholar
• Cabou C, Burcelin R. GLP-1, the gut–brain, and brain–periphery axes. Rev Diabet Stud 2011;8:418-31
   PubMedGoogle Scholar
• Seino Y, Rasmussen MF, Nishida T, et al. Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: results of a 52-week, randomized, multicenter trial. J Diabetes Investig 2011;2:280-6
   PubMed Web of Science ®Google Scholar
• Vilsboll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007;30:1608-10
   PubMed Web of Science ®Google Scholar
• Kanoski SE, Rupprecht LE, Fortin SM, et al. The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide. Neuropharmacology 2012;62:1916-27
   PubMed Web of Science ®Google Scholar
• Knudsen LB, Madsen LW, Andersen S, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010;151:1473-86
   PubMed Web of Science ®Google Scholar
• Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009;25:1019-27
   PubMed Web of Science ®Google Scholar
• Guidance for Industry. Diabetes mellitus – evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Washington, DC: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, 2008. Available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidance/ucm071627.pdf [Last accessed 29 October 2013]
   Google Scholar